Navigation Links
Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months

e patients:

-- Mild injection site reactions remain the most common side effect


-- Injection site reactions did not worsen with longer-term dosing and

were not more prevalent in patients who self-administered mipomersen.

-- The incidence and severity of ALT elevations was less in the OLE study

than in the initial studies.

-- The maximal ALT seen in this study was 172 U/L.

-- No patient experienced an elevation of transaminase (ALT) associated

with increased bilirubin (Hy's Law). There were no bilirubins greater

than the upper limit of normal (ULN) observed in any subject.

-- Several patients who experienced increased ALTs either in the OLE

study or in the initial studies continued to receive mipomersen and

experienced decline in ALTs. No patient who experienced increased

ALTs greater than three times the ULN in their initial trial had

increased ALT values when they were retreated with mipomersen in the

OLE study.

"This open-label extension study suggests that mipomersen can be administered with a satisfactory safety profile and continued LDL reductions for prolonged periods of time in patients with familial hypercholesterolemia being treated with maximal doses of statins and other lipid lowering agents," said Evan Stein, M.D., Ph.D., Director, Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio.

Conference Call Information

At 8:30 a.m. Eastern Time Monday, April 14, Isis will conduct a live webcast conference call to discuss mipomersen safety results. Interested parties may access the webcast at or listen to the call by dialing 877-856-1960. A webcast replay will be available for a limited time.


On January 7, 2008, Isis announced the licensing of mipomersen to Genzyme as

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
2. Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
6. Anti-Cancer Drug CYT997 Update
7. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
10. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
11. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
Post Your Comments:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Orthopedic Instrument Industry Report, 2014-2017" report to their ... and rising proportion of reimbursement for medical expenses, the ... with its scale presenting a CAGR of 19.2% during ... three product segments of orthopedic instruments in ...
(Date:8/29/2014)... According to a new ... type (SFE, Cold Pressed, Organic Solvent, & Others), and ... Fragrance, & Others) - Global Trends & Forecast ... the Amaranth Seed Oil Market with an analysis ... of value. The Amaranth Seed Oil Market size ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2
... Aug. 10, 2011 GNS Healthcare, Inc., (GNS) ... personalized medicine to improve human health, today announced ... Bristol-Myers Squibb Company (NYSE: BMY ) ... and biomarkers in the area of immuno-inflammation.  Utilizing ...
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) announced today ... will present at the Wedbush Securities 2011 Life Sciences Management ... on Tuesday, August 16, 2011. This presentation ... Relations section of Ardea,s website at . Please ...
Cached Medicine Technology:GNS Healthcare Announces Collaboration With Bristol-Myers Squibb 2Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference 2
(Date:8/29/2014)... of clinical trials based on administering antidepressants for ... that more trials are needed to determine whether ... on a regular basis., Dr. Ian Gilron, a ... the Department of Anesthesiology, and his team of ... the use of antidepressants for pain relief post-surgery ...
(Date:8/29/2014)... 2, 2014) A team of scientists from the ... breakthrough discovery of a process to expand production of ... could have implications that extend beyond cancer, including treatments ... In an article published Aug. 29 in ... Gates Center for Regenerative Medicine and Stem Cell Biology ...
(Date:8/29/2014)... 29, 2014, 2 PM US Eastern Time)The current ... inject antibodies, commonly produced in animals, to neutralize ... from safety to difficulties in developing, producing and ... New research led by Charles Shoemaker, Ph.D., professor ... Health at the Cummings School of Veterinary Medicine ...
(Date:8/29/2014)... new study from the research group of Dr. John Lewis ... Health Research Institute (London, ON) has confirmed that "invadopodia" play ... published in Cell Reports , shows preventing these tentacle-like ... , Roughly 2 in 5 Canadians will develop cancer ... die of the disease. In 2014, it,s estimated that nine ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Top10inaction, a ... web conference providers in the online service industry for ... were global leaders Webex, GotoMeeting and Infinite. , With ... users have to determine which provider is ideally a ... conference businesses search for compelling consumer goods and services ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... of Medicine (BUSM), Management (SMG) and Law (LAW), along ... that public-sector research has had a more immediate effect ... findings, which appear as a Special Article in the ... of Medicine , have economic and policy implications. ...
... HealthDay Reporter , WEDNESDAY, Feb. 9 (HealthDay ... cell genome revealed never-before-seen changes in DNA that may ... mapping the full genetic blueprint of the tumor, researchers ... of more targeted drugs and a better understanding of ...
... investing in public parks and recreation sites may be ... healthcare system, according to Penn State researchers. Investments in ... health and fitness, say Geof Godbey, professor emeritus of ... and parks management. "There is a strong relationship between ...
... heart disease, cancers, HIV and other diseases quickly and ... microsponges are an essential component of Rice University,s Programmable ... in the journal Small . The ... and Chemistry, and his colleagues at Rice,s BioScience Research ...
... Family Physicians demonstrates that vulvar cancer occurs most frequently in women ... with vulvar cancer are age 70 or older, and the rate ... by 75 years of age. , A team of researchers headed ... in Women,s Oncology at Women & Infants Hospital of Rhode Island, ...
... Poor memory and problems with other mental skills may be early ... Researchers gave a word recall memory test to 17,851 people, ... measure the brain,s executive functioning skills. The participants, who were aged ... stroke, were then contacted twice a year for up to 4.5 ...
Cached Medicine News:Health News:Researchers find public sector research responsible for many new drug discoveries 2Health News:Researchers find public sector research responsible for many new drug discoveries 3Health News:First Look at Prostate Cancer Genome Yields Insights 2Health News:First Look at Prostate Cancer Genome Yields Insights 3Health News:Key to better health care may be a walk in the park 2Health News:Microsponges from seaweed may save lives 2Health News:Microsponges from seaweed may save lives 3Health News:Researchers: Elderly patients 4 times more likely to die from treatment complications 2Health News:Could Poor Memory Signal Raised Stroke Risk? 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: